MBX Biosciences Will Participate in November Conferences
Company leaders are scheduled to present at three upcoming healthcare and biopharma investor events.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you typically adjust your investment strategy based on information shared at company investor conferences?
MBX Biosciences executives will participate in three separate investor conferences throughout November 2026. The series of events begins on November 10, 2026, and features engagements in both Boston and London.
Why it matters
These appearances provide a platform for the clinical-stage biopharmaceutical company to discuss its current pipeline and corporate progress. Stakeholders can access live webcasts of the presentations to gain insight into the company’s development programs.
The company’s clinical pipeline includes Canvuparatide for chronic hypoparathyroidism in Phase 3 and MBX 4291 in Phase 1. Two additional candidates, MBX 5765 and MBX 6180, are currently in preclinical development.
The players
Steve Hoerter
He is an executive representing MBX Biosciences at upcoming investor conferences.
Sam Azoulay
He is an executive representing MBX Biosciences at upcoming investor conferences.
MBX Biosciences
This clinical-stage biopharmaceutical company maintains offices in Carmel, Indiana, and Burlington, Massachusetts.
The details
Executives Steve Hoerter and Sam Azoulay will represent the biopharmaceutical firm through a series of fireside chats and one-on-one meetings. The company will host live webcasts for all three sessions on its website, with replays available two hours after completion.
Timeline
November 10, 2026: Guggenheim Healthcare Innovation Conference in Boston, MA at 11:00 - 11:25 a.m. EST.
November 17, 2026: UBS Global Biopharma Conference in London, UK at 8:00 - 8:30 a.m. GMT.
November 18, 2026: Jefferies Global Healthcare Conference in London, UK at 4:00 - 4:25 p.m. GMT.
The Tech Race
These conference appearances highlight the ongoing development of Canvuparatide for chronic hypoparathyroidism, currently the company’s lead asset in Phase 3. This effort mirrors the broader industry trend of biopharma firms accelerating clinical-stage programs through increased investor transparency.
Interested parties and potential investors can monitor the company’s pipeline progress by tuning into the live webcasts from their devices. These sessions allow stakeholders to evaluate the firm’s development trajectory in real time without needing to attend the conferences in person.
The takeaway
Interested followers can mark their calendars for mid-November to catch these scheduled updates on the company's clinical pipeline. Proactive investors should bookmark the company's events page to ensure they do not miss the 90-day window for archived session replays.
What happens next
Webcast replays for the conferences will be available on the company website two hours after each event concludes and will remain archived for 90 days.
Further reading
For more information on the industry, visit the Biotech section.
More information
To view the event schedule and access webcasts, visit the MBX Biosciences investor events portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you typically adjust your investment strategy based on information shared at company investor conferences?
